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Abstract
Background: Prediction of left ventricular (LV) remodeling after acute myocardial infarction (MI) is clinically
important and would benefit from the discovery of new biomarkers.
Methods: Blood samples were obtained upon admission in patients with acute ST-elevation MI who underwent
primary percutaneous coronary intervention. Messenger RNA was extracted from whole blood cells. LV function
was evaluated by echocardiography at 4-months.
Results: In a test cohort of 32 MI patients, integrated analysis of microarrays with a network of protein-protein
interactions identified subgroups of genes which predicted LV dysfunction (ejection fraction ≤ 40%) with areas
under the receiver operating characteristic curve (AUC) above 0.80. Candidate genes included transforming growth
factor beta receptor 1 (TGFBR1). In a validation cohort of 115 MI patients, TGBFR1 was up-regulated in patients
with LV dysfunction (P < 0.001) and was associated with LV function at 4-months (P = 0.003). TGFBR1 predicted LV
function with an AUC of 0.72, while peak levels of troponin T (TnT) provided an AUC of 0.64. Adding TGFBR1 to
the prediction of TnT resulted in a net reclassification index of 8.2%. When added to a mixed clinical model
including age, gender and time to reperfusion, TGFBR1 reclassified 17.7% of misclassified patients. TGFB1, the
ligand of TGFBR1, was also up-regulated in patients with LV dysfunction (P = 0.004), was associated with LV
function (P = 0.006), and provided an AUC of 0.66. In the rat MI model induced by permanent coronary ligation,
the TGFB1-TGFBR1 axis was activated in the heart and correlated with the extent of remodeling at 2 months.
Conclusions: We identified TGFBR1 as a new candidate prognostic biomarker after acute MI.
Background
Left ventricular (LV) remodeling after acute myocardial
infarction (MI) sets the stage for the development of
heart failure (HF). In spite of modern reperfusion thera-
pies, morbidity and mortality of HF post MI remain ele-
vated, with a 5-year prevalence of 63 to 76% [1,2]. A
rapid and accurate prediction of the development of HF
after MI would be a major breakthrough since HF is
potentially preventable [3].
Several factors determine the magnitude of LV remo-
deling and dysfunction, including infarct size and other
clinical variables such as age, gender and time to reper-
fusion. These factors have conventionally been used to
predict remodeling after acute MI [4]. Circulating bio-
markers such as troponins and natriuretic peptides have
the potential to improve this prediction and to select
patients for new biological or mechanical therapies.
However, existing biomarkers are not accurate prognos-
tic indicators of the development of LV remodeling and
HF after acute MI.
In recent studies, we have implemented integrated
strategies based on the concepts of systems biology to
identify new prognostic biomarkers of LV remodeling
[5-8]. Approaching LV remodeling with systems-based
technologies is a prerequisite to address the complexity
of LV remodeling. Some of these studies relied on the
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remodeling and participate in cardiac repair. Indeed,
intracoronary myocardial contrast echocardiography and
magnetic resonance imaging have shown that microvas-
cular perfusion greatly affects LV remodeling [9-11].
However, angiogenesis is certainly not the only regulator
of LV remodeling. A transcriptomic profile of angio-
genic factors has been revealed [12] and we have
reported the capacity of transcriptional networks in
blood cells to characterize LV remodeling [8,13].
In the present study, we implemented a combined
analysis of transcriptomic profiles of blood cells from
MI patients and protein interaction networks of angio-
genic proteins to identify new biomarkers of LV
remodeling.
Results
Patient selection and characteristics of the test cohort
Patients presenting with acute ST-elevation MI, treated
with primary percutaneous revascularization, were
enrolled in this study. Blood samples were obtained at
the time of mechanical reperfusion. A test cohort of two
groups of 16 patients selected based on their EF 4
months after MI (Table 1) was used for transcriptomic
analyses. One group of patients had a preserved LV sys-
tolic function with high EF after MI (> 40%, median
63%, range 45-73), and the other group impaired LV
function with low EF (≤ 40%, median 35%, range 20-40).
Demographic features of these 2 groups were similar,
except for infarct size as indicated by higher levels of
TnT and CPK in the low EF group.
Transcriptomic analysis of blood cells
Gene expression profiles of whole-blood cells were
obtained using 25,000 genes microarrays [14]. 525 genes
were found differentially expressed between high and
low EF patients with a 1.3-fold change threshold. Of
note, the 5% threshold for statistical significance was
reached for 54% of these genes. 226 genes were up-regu-
lated in the high EF group and 299 were up-regulated in
the low EF group. Using gene set enrichment analysis
(GSEA), we retrieved the 50 genes most significantly
associated with one or the other group of patients. The
heat-map drawn with the expression data of these 50
Table 1 Clinical characteristics.
Test cohort Validation cohort
High EF Low EF P value
(n = 16) (n = 16) (high vs low EF) (n = 115)
4-months EF, % (median-range) 63 45-73 35 20-40 0.0003 40 15-86
Age, y (median-range) 56 43-84 68 38-83 0.57 56 32-90
Sex (male, n, %) 13 81% 13 81% 1 98 85%
Body Mass Index (median-range) 28 23-35 26 20-38 0.25 27 19-43
Serum markers (median-range)
Troponin T (ng/mL) 0.78 0.06-10.69 11.64 1.46-26.1 0.007 4.76 0.03-26.1
CPK (units/L) 762 603-3798 4860 1015-9383 < 0.001 1978 602-9383
Cardiovascular history, n (%)
Prior MI 2 13% 3 19% 0.64 7 6%
CABG 0 0% 1 6% 0.33 3 3%
PTCA 1 6% 2 13% 0.56 11 10%
Diabetes 4 25% 6 38% 0.46 22 19%
Hypertension 6 38% 7 44% 0.73 47 41%
Hypercholesterolemia 7 44% 9 56% 0.50 45 39%
Tobacco 4 25% 5 31% 0.71 53 46%
Medications, n (%)
Beta-blockers 16 100% 14 88% 0.16 98 85%
Calcium antagonists 3 19% 0 0% 0.08 0 0%
Nitrates 6 38% 6 38% 1 31 27%
ACE inhibitors 10 63% 10 63% 1 51 44%
Statins 14 88% 14 88% 1 89 77%
Angiotensin receptor inhibitors 2 13% 0 0% 0.16 1 1%
All MI patients had successful mechanical reperfusion and stenting of the infarct artery within 12 hours of chest pain onset. All patients received Aspirin,
Clopidogrel, Heparin and Abciximab in the presence of a large thrombus.
ACE: Angiotensin Converting Enzyme; CABG: Coronary Artery Bypass Grafting; EF: Ejection Fraction; PTCA: Percutaneous Transluminal Coronary Angioplasty; MI:
Myocardial Infarction.
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MI is associated with a specific biosignature of blood
cells obtained the day of MI (Figure 1A).
Angiogenic genes associated with clinical outcome after
MI
There is ample evidence that angiogenesis plays a signif-
icant role in LV remodeling after MI. We therefore
aimed to identify among the 525 genes differentially
expressed between high and low EF patients the genes
related to angiogenesis. For this purpose, we retrieved
f r o mt h eE n t r e zG e n ed a t a b a s eal i s to f4 9 4g e n e s
known to be related to angiogenesis in humans with the
following query: “angiogenesis” AND “homo sapiens”.
We assigned to these 494 genes the expression values of
the test cohort obtained by microarrays. 28 genes were
found differentially expressed: 20 genes were up-regu-
lated in the low EF group and 8 genes were up-regu-
lated in the high EF group (Figure 1B).
Building of a network of protein-protein interactions
We implemented an interaction network of proteins
know to be involved in angiogenesis, a process involved
in LV remodeling. For this purpose, we retrieved from
the Human Protein Reference Database all known inter-
actions between the 28 proteins encoded by the 28
genes differentially expressed between the 2 groups of
patients from the test cohort (Figure 1B). The network
built with these interactions is represented in Figure 2A,
and contains 441 nodes (proteins) and 458 edges (inter-
actions). It has to be noted that the proteins PBEF1 and
PFKFB3 did not have known protein-protein interaction.
Figure 1 Gene Set Enrichment Analysis (GSEA) of expression profiles of blood cells from MI patients. Gene expression profiles of blood
cells from two groups of 16 MI patients having either high EF (> 40%) or low EF (≤ 40%) were obtained by 25,000 genes oligonucleotide
microarrays. After normalization and filtering steps, expression data were analyzed by GSEA and are visualized by heat-maps. Colors (red, pink,
light blue, dark blue) show the range of expression values (high, moderate, low, lowest, respectively). Black boxes denote missing values. (A)
Expression ranges of the 50 most differentially expressed genes showing distinct transcriptomic biosignatures between patients with high and
low EF. (B) Among the 525 differentially expressed genes between high and low EF patients, 28 genes were involved in angiogenesis according
to the Entrez Gene database resource: 20 genes were up regulated in the low EF group and 8 genes were up regulated in the high EF group. A
heat-map representing the expression values of these 28 genes is shown.
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interconnected proteins. This was based on the assump-
tion that highly interacting proteins may have important
biological functions. Nine clusters from 9 to 35 proteins
were identified (Table 2).
Prognostic performances of clusters of angiogenic genes
To determine the prognostic value of the genes of the
clusters identified by network analysis, we used the
expression values obtained by microarrays in the two
groups of MI patients of the test cohort. To limit our
investigations to a reasonable number of genes, we
focused on the 16 genes of cluster 6 (Table 2). Of these
genes, TGFBR2 and SUMO4 were not detected by
microarrays. The sub-network formed by the 16 genes is
displayed in Figure 2B. Logistic regression models attrib-
uted the best predictive value to a group of 3 genes:
TGFBR1, PTK2 and ITK (AUC = 0.89). These 3 genes
classified patients into low EF and high EF groups with
87% sensitivity (Table 3).
Figure 2 Protein-protein interaction network. A global network (A) was built from 441 proteins (nodes) and 458 interactions (edges). Green
nodes represents the 16 proteins of cluster 6 used to built the subnetwork (B).
Table 2 Subsets of angiogenic genes associated with LV function.
Cluster Protein
number
Interaction
number
MCODE
score*
Genes
1 3 4 1 TGFBR1, TGFBR2, CLU
2 5 7 1 TGFBR1, TGFBR2, CLU, MAP3K7, FOS
3 10 16 1.3 TGFBR1, TGFBR2, CLU, MAP3K7, FOS, SUMO4, STAT1, PTK2, BMX, CAV1
4 12 20 1.42 TGFBR1, TGFBR2, CLU, MAP3K7, FOS, SUMO4, STAT1, PTK2, BMX, CAV1, ITK, PAK1,
5 13 22 1.38 TGFBR1, TGFBR2, CLU, MAP3K7, FOS, SUMO4, STAT1, PTK2, BMX, CAV1, ITK, PAK1, PTGS2
6 16 27 1.37 TGFBR1, TGFBR2, CLU, MAP3K7, FOS, SUMO4, STAT1, PTK2, BMX, CAV1, ITK, PAK1, PTGS2, FYN, LCK,
CD55
7 21 34 1.38 TGFBR1, TGFBR2, CLU, MAP3K7, FOS, SUMO4, STAT1, PTK2, BMX, CAV1, ITK, PAK1, PTGS2, FYN, LCK,
CD55, ATP5B, SRC, MYOC, ANXA2, PLG
8 28 44 1.32 TGFBR1, TGFBR2, CLU, MAP3K7, FOS, SUMO4, STAT1, PTK2, BMX, CAV1, ITK, PAK1, PTGS2, FYN, LCK,
CD55, ATP5B, SRC, MYOC, ANXA2, PLG, SOD1, BCL2, MAPK14, SMAD7, SHC1, MME, ADM
9 35 55 1.34 TGFBR1, TGFBR2, CLU, MAP3K7, FOS, SUMO4, STAT1, PTK2, BMX, CAV1, ITK, PAK1, PTGS2, FYN, LCK,
CD55, ATP5B, SRC, MYOC, ANXA2, PLG, SOD1, BCL2, MAPK14, SMAD7, SHC1, MME, ADM, CFH,
THBS1, KNG1, PLAUR, PRKCA, RAB25
*MCODE cluster score = density * number of nodes.
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To confirm the results obtained from the test cohort, we
measured the expression of TGFBR1, PTK2 and ITK by
quantitative PCR in blood cells from a validation cohort
of 115 acute MI patients. Demographic features of these
patients are shown in Table 1. As for the test cohort,
blood samples were obtained at presentation and follow-
up was performed at 4-months by echocardiography. Of
the 3 candidate genes, TGFBR1 was the most robustly
associated with LV function. PTK2 and ITK were not
significantly correlated with the EF (data not shown).
TGFBR1 expression was inversely correlated with the EF
(r = -0.28, P = 0.003) and was higher in patients with
LV dysfunction (Figure 3A). Linear regression analyses
attested that TGFBR1 was associated with LV dysfunc-
tion at 4-months (P = 0.003). The serum markers crea-
tine phosphokinase and troponin T predicted TGFBR1
expression (P = 0.03 and P = 0.003 by linear regression,
respectively), suggesting that TGFBR1 is responsive to
infarct size. All together, these results show that
TGFBR1 expression is associated with LV function in an
independent cohort.
Prognostic performance of TGFBR1
The prognostic value of TGFBR1 in the cohort of 115
acute MI patients was first evaluated using ROC curve
analysis, which reported an AUC of 0.72 (Figure 3B). As
a comparison, peak levels of TnT and CPK provided an
A U Co f0 . 6 4( F i g u r e3 B ) .C P Ko rt r o p o n i nTd i dn o t
improve the prognostic value of TGFBR1 (not shown),
suggesting that this value is independent of infarct size.
Reclassification analyses reported a NRI of 8.2% when
TGFBR1 was added to TnT prediction (Table 4).
In the validation cohort, 7 patients (6%) had a pre-
vious MI (Table 1). In the 108 patients who presented
with a first MI, the predictive value of TGFBR1 had an
AUC of 0.72, identical to the AUC reported for the
whole validation cohort (Figure 3B). Therefore, although
it is expected that a population of patients with first
infarcts would better reflect post-MI LV remodeling, the
presence of few patients with a second infarct did not
affect the predictive value of TGFBR1.
We next investigated the additive value of TGFBR1 to
a mixed clinical model including age, gender and time
to reperfusion, all known to determine the extent of LV
remodeling. We observed significant correlations
between the EF measured at 4-months and each of
these parameters, patients of older age (R = -0.35, P =
0.0002), females (R = 0.20, P = 0.02), and presenting late
after chest pain onset (R = -0.26, P = 0.007) having the
h i g h e s tr i s ko fi m p a i r e dE F( E F≤ 40%). By multiple
logistic regression, however, only age was a significant
predictor of impaired EF (P < 0.001). The clinical model
predicted LV function with an AUC of 0.73 (Figure 3C),
comparable to the AUC provided by TGFBR1 alone
(AUC = 0.72, Figure 3B). Adding TGFBR1 to the clinical
model increased its AUC to 0.76 (Figure 3C). Reclassifi-
cation analyses attested that TGFBR1 was able to reclas-
sify 17.7% of patients misclassified by the clinical model
(Table 5).
Together, these data confer a significant prognostic
value to TGFBR1.
Prognostic performance of TGFB1
We then evaluated the ability of TGFB1, the ligand of
TGFBR1, to predict LV dysfunction. TGFB1 was mea-
sured in the plasma obtained at presentation in the 115
patients of the validation cohort. As observed for
TGFBR1, TGFB1 was inversely correlated with EF (r =
-0.20, P = 0.04) and was over-expressed in patients with
LV dysfunction (Figure 3D). Linear regression revealed a
significant association between TGFB1 and LV dysfunc-
tion (P = 0.006) and ROC curves reported a modest
prognostic value with an AUC of 0.66 (Figure 3E). Add-
ing TGFB1 to TGFBR1 did not result in a statistically
detectable improvement in prediction (not shown).
Therefore, TGFB1 is also associated with LV function
but does not provide an additive value to TGFBR1.
The TGFB1-TGFBR1 axis in the heart
To investigate the physiological relevance of our find-
ings, we subjected rats to LAD-occlusion, a standard
animal model of MI. The amount of total TGFB1 in the
heart was increased 2 months after MI (Figure 4A).
Table 3 Prognostic performances of subsets of angiogenic genes.
Proteins AUC True positive rate (%) False positive rate (%)
TGFBR1, CLU, MAP3K7, FOS, STAT1, PTK2, BMX, CAV1, ITK, PAK1, PTGS2, FYN, LCK, CD55 0.67 62 38
CLU, FOS, ITK, PTGS2, LCK, CD55 0.83 69 31
FOS, LCK, CLU 0.84 69 31
ITK, LCK, CD55 0.82 72 28
ITK, CD55 0.84 75 25
TGFBR1, PTK2, ITK 0.89 87 13
Logistic regression models were used for these analyses. AUC: area under the receiver operating characteristic (ROC) curve. True positive rate (= sensitivity)
indicates the percentage of patients correctly classified in the EF group (EF ≤ 40% or EF > 40%). False positive rate (= 1-specificity) indicates the percentage of
patients misclassified in the EF group. Optimal classification models are shown; all other combination of genes provided lower classification performances.
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Figure 3 Expression levels and prognostic values of TGFBR1 and TGFB1. Blood samples from 115 MI patients obtained upon admission
were used to measure TGFR1 mRNA expression in blood cells by quantitative PCR and TGFB1 plasma level by ELISA. TGFBR1 mRNA expression
was normalized to SF3A1. (A and D) Box-plots showing that TGFBR1 and TGFB1 are over-expressed in patients with LV dysfunction (EF ≤ 40%)
compared to patients with preserved LV function (EF > 40%) assessed at 4-months follow-up. The lower boundary of the box indicates the 25th
percentile, the line within the box marks the median, and the upper boundary of the box indicates the 75th percentile. Whiskers (error bars)
above and below the box indicate the 90th and 10th percentiles. (B-C-E) ROC curve analysis showing the performance of TGFBR1 and TGFB1
measured at presentation, peak levels of TnT and CPK, and a mixed clinical model (Clin mod; including age, gender and time to reperfusion) to
predict LV dysfunction. AUCs are indicated.
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Page 6 of 13However, the amount of activated TGFB1 was not
increased (not shown), suggesting that the up-regulation
of TGFB1 expression in the heart of MI animals reflects
an increase of the latent form. Total TGFB1 expression
did not significantly correlate with LV function, as
assessed by the EF at 2-months (Figure 4B). Interest-
ingly, there was a positive correlation between TGBF1
and LV remodeling, as assessed by the variation of end-
diastolic and end-systolic volumes between 48 hours
and 2 months after MI. Rats with the largest degree of
remodeling (increased LV volumes) had the highest
levels of TGFB1 (Figure 4C-D).
Faintly expressed in the heart of healthy animals
(sham), TGFBR1 was up-regulated in the border zone
but not in the remote zone 2-months after MI (Figure
4 E ) .T G F B R 1w a sh i g h l ye x p r e s s e d2w e e k sa f t e rM I ,
but not after 2 days (Figure 4F). Trichrome Masson
staining showed the presence of collagen deposition and
fibrosis in the necrotic part of the heart after 2 months
(Figure 4G). Therefore, the TGFB1-TGFBR1 axis is acti-
vated in cardiac tissue after experimental MI in rats and
correlates with LV remodeling.
Discussion
Based on the concepts of systems biology, this study was
designed to identify new prognostic biomarkers after
acute MI. First, using a test cohort of 32 patients, we
observed that LV dysfunction after MI (4-months EF <
40%) had a biosignature in blood cells in the acute
phase. Among the genes associated with LV dysfunction,
28 were linked to angiogenesis, which is known to play
a key role in cardiac repair. Then, using clustering ana-
lysis of a network of protein-protein interactions built
with these 28 angiogenic genes, we isolated a group of 3
genes -TGFBR1, PTK2, ITK- which predicted LV func-
tion with and AUC of 0.89. In an independent validation
cohort of 115 MI patients, TGFBR1 was found to have a
prognostic value which may become clinically useful.
Finally, we showed that the TGFB1-TGFBR1 is activated
after MI in rats and correlates with the extent of
remodeling.
Left ventricular remodeling is a highly complex phe-
nomenon involving diverse biological processes, such as
inflammation, regulation of extracellular matrix turn-
over, fibrosis, cell death, and angiogenesis. Such com-
plex diseases can be approached with systems-based
concepts. We chose angiogenesis to filter the relatively
high number of genes (525) found to be differentially
expressed between patients with or without LV dysfunc-
tion. It is clear that other family of genes involved in
remodeling may also be worth studying. It is expected
that genes involved in multiple biological pathways or
sharing many interactions with other genes may be
m o r es u s c e p t i b l et op l a ys i g nificant roles in remodeling
and have a prognostic value. Accordingly, TGFBR1 was
an o d ei nt h en e t w o r ko f1 6a n g i o g e n i cp r o t e i n ss h o w n
in Figure 2B and was connected to 6 other proteins,
suggesting a central role in angiogenesis. A more global
approach, which could be used for future studies, would
be to widen the search for biomarkers to all pathways
known to play a role in LV remodeling, and not to
restrain to a specific pathway such as angiogenesis.
Transcriptional profiling has emerged as an interesting
tool to study cardiovascular diseases and ultimately to
personalize therapeutic strategies [15]. A key feature of
our study is the use of readily available blood cells,
rather than cardiac biopsies. While it may be argued
that transcriptomic analysis of cardiac tissues would
more accurately reflect the myocardial response to MI,
it is accepted that several cardiovascular conditions
including coronary artery disease [16] and chronic HF
[17] are characterized by specific transcriptomic bio-
signatures in blood cells. Our study shows for the first
time that TGFBR1 expression level in blood cells
Table 4 Reclassification performance of TGFBR1 over TnT.
TnT TnT + TGFBR1
Class EF > 40% EF ≤ 40% Correctly classified (%) EF > 40% EF ≤ 40% Correctly classified (%) NRI (%)
EF > 40% 32 23 59.3 38 20 70.4
EF ≤ 40% 22 38 62.2 16 41 67.2
Total 54 61 60.1 54 61 68.7 8.2
Correct classifications appear in bold. NRI: net reclassification index.
Table 5 Reclassification performance of TGFBR1 over a clinical model including age, gender and time to reperfusion.
Clinical model Clinical model + TGFBR1
Class EF > 40% EF ≤ 40% Correctly classified (%) EF > 40% EF ≤ 40% Correctly classified (%) NRI (%)
EF > 40% 43 22 79.6 43 17 79.6
EF ≤ 40% 11 39 63.9 11 44 72.1
Total 54 61 71.3 54 61 75.6 17.7
Correct classifications appear in bold. NRI: net reclassification index.
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Figure 4 The TGFB1-TGFBR1 axis in rats after MI. 17 rats were subjected to MI through permanent ligation of the LAD coronary artery. 4 rats
were sham-operated. Rats were assessed by PET to determine LV volumes and EF 48 hours and 2 months after ligation. Rats were sacrificed after
2 days (n = 3), 2 weeks (n = 3) or 2 months (n = 11). At sacrifice, hearts were harvested. (A) Total TGFB1 measured by ELISA in cardiac samples
is up-regulated 2 months after MI. Data are expressed in pg of TGFB1 per μg of total cardiac proteins. Shown are mean ± 95% CI (n = 4 for
sham, n = 11 for MI). (B) TGFB1 expression in the heart mildly correlates with 2-months EF. (C-D) TGFB1 expression correlates with the variations
of LV end-diastolic and end-systolic volumes between 48 hours and 2 months. Correlation coefficients and P values are indicated. (E)
Immunohistochemical analysis of TGFBR1 expression in cardiac slices. The technical control without anti TGFBR1 antibody attests for the
specificity of the detection. TGFBR1 staining appears in red colour and nuclei appear in blue. TGFBR1 expression is up-regulated in the border
zone of MI rats. Representative pictures of sham-operated rats (upper panels) and MI rats (lower panels) are shown. (F) TGFBR1 expression in the
border zone 2 days and 2 weeks after MI. TGFBR1 expression is up-regulated in the border zone 2 weeks after MI. Representative pictures are
shown. (G) Masson trichrome staining showing collagen deposition and fibrosis in the necrotic zone of the heart 2 months after MI.
Representative pictures from a MI rat are shown.
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Page 8 of 13obtained at presentation in acute MI patients has prog-
nostic value for long-term LV remodeling.
In addition, we have observed an association between
TGFB1, which has prognostic values for remodeling and
hypertrophy in patients with hypertension and aortic
stenosis [18,19], and LV function. This association was
n o ta sr o b u s ta sT G F B R 1 ,a n dt h ep r o g n o s t i cv a l u eo f
T G F B R 1w a sn o tf o u n dt ob ei m p r o v e db yT G F B 1
determination. Interestingly, TGFBR1 added some value
to the prediction of TnT, a marker of infarct size known
to affect LV remodeling. The reclassification of 8.2% of
patients misclassified by TnT is clinically relevant. Simi-
larly, the reclassification of 17.7% of patients misclassi-
fied by a standard risk factor model based on age,
gender and time to reperfusion, is pertinent.
The integration of multiple biomarkers is thought to
improve the estimation of the course of cardiovascular
diseases [20], although this assumption has been ques-
tioned [21]. Heidecker and coworkers reported that a
group of 45 genes identified from endomyocardial biop-
sies predicted 5-year outcome of new onset HF patients
with a sensitivity of 74% and a specificity of 90% [22].
More recently, a panel of 5 plasma proteins involved in
extracellular matrix turnover was demonstrated to be a
more accurate predictor of LV hypertrophy than any
single biomarker [23]. Alternatively, combining biomar-
kers representing diverse disease mechanisms has also
been shown to add incremental risk stratification value
in patients with non ST-elevation acute coronary syn-
drome [24]. Our data showing that TGFBR1 has an
additive value to traditional markers are consistent with
the concept that multiplication of biomarkers may be
clinically useful.
More than 80% of the patients enrolled in this study
were males. The low number of females enrolled (6 in
the test cohort and 17 in the validation cohort) pre-
vented us from investigating whether gender contributes
to the prognostic value of TGFBR1. However, TGFBR1
expression was not different between women and men
(not shown), suggesting that gender may not influence
the prognostic value of TGFBR1.
Activation of the TGFB1-TGFBR1 pathway is mainly
associated with stimulation of fibrosis, although it also
affects LV hypertrophy, matrix metabolism, inflamma-
tion, and angiogenesis [25-27]. After MI, this pathway
triggers the switch from inflammation to fibrosis
[28-30]. TGFBR1 expression has been reported to be
higher in the infarcted region of pig hearts after perma-
nent coronary ligation compared to the remote region
[31]. Our data in rats confirm and extend these observa-
tions. It is believed that biomarkers should reflect the
pathophysiology, and our experiments in rats provide
valuable proof for this. Inhibition of TGFBR1 activity by
orally active specific inhibitors [28,32] or competitive
inhibition of TGFB1 by a soluble form of TGFBR2 [33]
dampens cardiac remodeling after MI. Other strategies
to block TGFB, which have been recently reviewed [34],
may also be tested to limit cardiac remodeling
Endothelial progenitor cells participate in cardiac
revascularization and healing after acute MI. However,
considering their extremely low frequency in the circula-
tion, these cells are certainly not the main source of
TGBFR1 signal measured by microarrays. Circulating
monocytes-macrophages may most probably account for
the majority of TGFBR1 expression. Interestingly, these
cells secrete many cytokines, growth factors and fibrotic
factors which regulate LV remodeling and cardiac heal-
ing. The higher expression of TGFBR1 in patients with
low EF is consistent with the more robust activation of
inflammation observed in these patients, as attested by
higher white blood cells counts (not shown). Whole
blood cells profiling can be affected by shifts in leuko-
cyte populations. However, the proportions of circulat-
ing monocytes were comparable between patients with
low EF and patients with high EF, suggesting that this
confounding factor did not importantly affect our
results. It would be interesting to accurately determine
which cell type(s) express TGFBR1 in the heart, and
whether TGFBR1 expression is regulated in cells
involved in cardiac healing. The animal model of coron-
ary artery ligation used in the animal study is a valuable
tool to answer these questions.
The main limitation of the present study relies in the
small number of patients enrolled. This is particularly
relevant for the test cohort used in microarray experi-
ments. Nevertheless, using a different and quantitative
technique, we were able to validate our findings from
this small cohort in an independent cohort of more
than 100 patients. The relevance of our findings
depends on the confirmation of the prognostic value of
TGFBR1 in larger patient populations. In addition, all
human blood samples were collected at presentation
and measurement of TGFBR1 expression at different
time-points after acute MI could provide valuable
informations. Finally, mutations in TGFBR1 gene,
k n o w nt oa f f e c tv a s c u l a ri n t e g r i t yi nM a r f a na n d
Loeys-Dietz syndromes [35,36], have to be taken into
consideration for the design of probes to measure
TGFBR1 expression and for the design of specific ther-
apeutic inhibitors.
Conclusions
We have shown that TGFBR1 expression in blood cells
of acute MI patients is associated with LV remodeling.
If confirmed in independent studies, this new biomarker
may become clinically useful to identify patients with
acute MI who are at risk of adverse outcome and may
benefit from novel therapies.
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Patients
Patients with acute MI were enrolled in a national MI
registry and treated with primary percutaneous coronary
intervention. Acute MI was defined by the presence of
chest pain < 12 hours, significant ST elevation (> 1
mm), completely occluded major coronary artery (TIMI
O flow in LAD, CX or RCA), peak (≈ 24 hours) creatine
phosphokinase (CPK) level > 600 units/L and peak tro-
ponin T (TnT) level > 0.03 ng/mL. Blood samples
obtained shortly (5 min) after mechanical reperfusion,
via an arterial catheter and into PAXgene™ tubes (BD
Biosciences, Erembodegem, Belgium), were used for
determination of TGFBR1 expression. TGFB1 was mea-
sured in plasma extracted from citrated tubes collected
after mechanical reperfusion. Time to reperfusion was
recorded by dedicated nurses as the delay between chest
pain onset evaluated by the patient and presentation.
CPK activity was assessed with a Roche IFCC method
on a Cobas c501 instrument (Roche, Prophac, Luxem-
bourg). TnT was assessed with a 4
th generation assay
from Roche performed on a Cobas e601 equipment
(Roche). TGF-B1 was measured with the human TGF-
B1 ELISA kit (ref DB100B, R&D Systems, Oxon, UK).
LV function was assessed by echocardiography 4 months
after MI, and LV remodeling was defined by a LV ejec-
tion fraction (EF) ≤ 40%. The protocol has been
approved by the local ethics committee (National com-
mittee of ethics in research of the Grand-Duchy of Lux-
embourg) and informed consent has been obtained from
all subjects.
Microarrays
Transcriptomic analysis of blood cells was performed as
previously described [7]. Total RNA was extracted from
whole blood cells of MI patients using the PAXgene™
blood RNA kit (Qiagen, Venlo, Netherlands). A second
purification and concentration step was performed with
the RNeasy
® MinElute™ kit (Qiagen). RNA quantity
was measured using the ND-1000 spectrophotometer
(NanoDrop
® Technologies, Wilmington, USA). RNA
quality was assessed using the 2100 Bioanalyzer
® appa-
ratus (Agilent Technologies, Massy, France) with the
RNA 6000 Nano chips. Only high quality RNA (OD260/
OD280 >1 . 9a n dO D 260/OD230 >1 . 7 )a n du n - d e g r a d e d
RNA was considered for further analysis. A common
reference RNA (Universal Human Reference RNA, Stra-
tagene Europe, Amsterdam, The Netherlands) was used
in conjunction with patient’s RNA to provide an internal
reference standard for comparisons of relative gene
expression levels across arrays. Messenger RNAs were
amplified using the Amino Allyl MessageAmp™ kit
(Ambion
®, Cambridgeshire, United Kingdom), starting
with one μgo ft o t a lR N A .F i v eμg of each amino allyl
aRNA were labeled with Cy3 or Cy5 (Amersham, Buck-
inghamshire, United Kingdom). Dye coupling to RNA
was measured using the ND-1000 NanoDrop
® spectro-
photometer. Coupling yield > 5% was a prerequisite for
further analysis. 750 ng of each amino allyl aRNA
labeled Cy3 or Cy5 (reference RNA or patient RNA)
were combined and hybridized on oligonucleotide
microarrays representing 25,000 genes [14]. Four repli-
cates and a dye-swap were performed. Scanning was
performed with an Axon 4000B scanner and data were
acquired with the GenePix Pro 6
® software (Molecular
Devices, Berks, UK). Spot finding and raw data quantifi-
cation were performed using the MAIA
® freeware. A
Lowess non linear normalization was performed and
genes that were not present in at least 3 microarrays of
4 were filtered out. Data are available at the Gene
Expression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo/) under the accession number GSE11947.
Before statistical analysis, genes not present in at least
50% of the patients were filtered out. Supervised analysis
was performed using the Significance Analysis of Micro-
arrays software using 2-class unpaired test and 100 per-
mutations. Heat maps were drawn using the Gene Set
Enrichment Analysis (GSEA) software [37].
Quantitative PCR
The expression of mRNAs in blood cells of MI patients
obtained upon admission was determined by quantita-
tive PCR. Total RNA was extracted from blood cells col-
lected in PAXgene
® blood RNA tubes. PCR was
performed using a CFX96 device and the IQ™ SYBR
®
Green Supermix (BioRad, Nazareth, Belgium). SF3A1
was used for normalization.
Network of protein-protein interactions
Genes known to be associated with angiogenesis in
humans were retrieved from the Entrez-Gene database
[38] with the query: “angiogenesis” AND “homo
sapiens”. The Human Protein Reference Database
(release 9) [39] was then interrogated to identify all
annotated protein-protein interactions associated with
these genes. These interactions were used as inputs to
build a network, which was visualized and analyzed with
Cytoscape [40]. Clusters of highly interconnected pro-
teins were identified by the MCODE plug-in network
clustering algorithm [41].
In vivo experiments and biochemical analyses
Myocardial infarction was induced in 17 anesthetized
Wistar rats (Charles Rivers Laboratories; 8-11 weeks;
310-380 g) by permanent occlusion of the left anterior
descending (LAD) coronary artery as previously
described [42,43]. An additional 4 rats were sham-oper-
ated. All rats were monitored in vivo 48 hours after
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lution dedicated small animal positron emission tomo-
graphy (PET) system with
18F-FDG (IBA, Nancy, France)
as a tracer and a premedication by acipimox, as pre-
viously described [44]. LV end-diastolic volume
(LVEDV) was obtained on contiguous gated short-axis
slices by the Quantitative Gated SPECT software [45].
The extent of remodeling was assessed by the change in
LVEDV between 48-hours and 2-months after surgery
(Δ LVEDV). At sacrifice, blood samples were collected,
hearts were harvested, snap frozen and embedded in
OCT. Parts of cardiac tissue were rinsed in NaCl and
stored at -80°C for protein extraction. These experi-
ments were conducted in accordance with the regula-
tions of the Animal Welfare Act of the National
Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85-23, revised
1996) and protocols were approved by local Ethics
Committee and by the Regional Veterinary Department.
For immunohistochemistry and collagen-specific Mas-
son Trichrome staining (Dako, Leuven, Belgium), 8 μm
frozen heart sections were generated. Primary antibody
used was a rabbit polyclonal anti TGFBR1 antibody
(Abcam, Cambridge, UK). Alexa Fluor
®568-coupled
donkey anti-rabbit antibodies (Jackson ImmunoRe-
search, UK) were used as secondary antibodies. Images
were recorded on a confocal microscope (Zeiss Laser
Scanning Microscope LSM 510) with a 40× objective
using the LSM 510 META software. DAPI (blue) stain-
ing was used to reveal nuclei.
The TGFB1 ELISA kit (ref MB100B, R&D Systems)
was used to measure TGFB1 in cardiac tissue. 50 μgo f
total proteins from each heart were assayed. This assay
detects activated TGFB1 with a sensitivity of 4.6 pg/mL.
To measure total TGFB1, latent TGFB1 is activated by
acidification with hydrochloric acid prior to assay. Coef-
ficient of variation intra-assay is < 4% and coefficient
inter-assay is < 9%.
Statistical analysis
Comparisons between means of two groups were per-
formed with the Mann-Whitney test. Categorical vari-
ables were compared using the Fisher exact test.
Correlation between biomarker levels and the EF class
was estimated with the Spearman test. All tests were
two-tailed and were preceded by a normality test (Sha-
piro-Wilk). A P value < 0.05 was considered statistically
significant. The SigmaPlot (v. 11.0) was used to carry-
out statistical tests.
Prognostic performances of single genes were evalu-
ated using receiver operating characteristic (ROC)
curves and the area under the ROC curves (AUC), as
well as linear regression models. Logistic regression
models with ridge parameter of 1.0E-8 used to evaluate
the predictive performances of multiple markers were
implemented and tested using 10-fold cross-validation
on the Weka (v. 3.4) data mining platform [46].
Reclassification analyses have been performed to eval-
uate the additive value of TGFBR1 to TnT and to a
mixed clinical model. The net reclassification index
(NRI) was calculated as the difference in proportions
moving up and down among cases and controls: [Pr(up|
case)-Pr(down|case)]-[Pr(up|control)-Pr(down|control)].
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